Cogent Biosciences Files 8-K Report

Ticker: COGT · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1622229

Cogent Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyCogent Biosciences, INC. (COGT)
Form Type8-K
Filed DateJun 27, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: filing, corporate-actions

TL;DR

Cogent Biosciences filed an 8-K, mostly procedural stuff, but they used to be Unum Therapeutics.

AI Summary

On June 27, 2024, Cogent Biosciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." It also notes a former company name, Unum Therapeutics Inc., which changed its name on April 2, 2018.

Why It Matters

This filing provides official updates and disclosures from Cogent Biosciences, Inc. to the SEC, which can impact investor understanding of the company's status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not appear to contain any new material events or significant financial disclosures that would immediately alter risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Cogent Biosciences, Inc.?

The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of June 27, 2024.

What was Cogent Biosciences, Inc. formerly known as?

Cogent Biosciences, Inc. was formerly known as Unum Therapeutics Inc., with a name change date of April 2, 2018.

What is the SEC file number for Cogent Biosciences, Inc.?

The SEC file number for Cogent Biosciences, Inc. is 001-38443.

Where are Cogent Biosciences, Inc.'s principal executive offices located?

Cogent Biosciences, Inc.'s principal executive offices are located at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451.

What is the I.R.S. Employer Identification Number for Cogent Biosciences, Inc.?

The I.R.S. Employer Identification Number for Cogent Biosciences, Inc. is 46-5308248.

Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-06-27 08:05:31

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated June 27, 2024. 104 The cover page from the Company's Current Report on Form 8-K formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 27, 2024 COGENT BIOSCIENCES, INC. By: /s/ Evan Kearns Evan Kearns Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing